EPIDERMAL GROWTH FACTOR RECEPTOR C797S

Clinical trials for EPIDERMAL GROWTH FACTOR RECEPTOR C797S explained in plain language.

Never miss a new study

Get alerted when new EPIDERMAL GROWTH FACTOR RECEPTOR C797S trials appear

Sign up with your email to follow new studies for EPIDERMAL GROWTH FACTOR RECEPTOR C797S, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Not yet finished but already full! 1

New pill targets Tough-to-Treat cancers in brain and lungs

Disease control Ongoing

This study is testing an oral medication called BDTX-1535 for adults with advanced non-small cell lung cancer or glioblastoma (a type of brain tumor) that have specific genetic changes. The goal is to find the safest and most effective dose and see if the drug can shrink tumors, …

Matched conditions: EPIDERMAL GROWTH FACTOR RECEPTOR C797S

Phase: PHASE1, PHASE2 • Sponsor: Black Diamond Therapeutics, Inc. • Aim: Disease control

Last updated Mar 31, 2026 12:12 UTC

EPIDERMAL GROWTH FACTOR RECEPTOR C797S

Get alerted when new EPIDERMAL GROWTH FACTOR RECEPTOR C797S trials appear

New pill targets Tough-to-Treat cancers in brain and lungs